Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aerovate Therapeutics, Inc.

Aerovate Therapeutics to Explore Strategic Alternatives
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Tickers AVTE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS